4.7 Article

Interval Between Neoadjuvant Chemoradiotherapy and Surgery for Squamous Cell Carcinoma of the Thoracic Esophagus Does Delayed Surgery Have an Impact on Outcome?

Journal

ANNALS OF SURGERY
Volume 252, Issue 5, Pages 788-795

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/SLA.0b013e3181fc7f86

Keywords

-

Categories

Ask authors/readers for more resources

Objective: Aim of this study was to evaluate whether delayed surgery after neoadjuvant chemoradiotherapy (CRT) affects postoperative outcomes in patients with locally advanced squamous cell carcinoma (SCC) of the thoracic esophagus. Background: Esophagectomy is usually recommended within 4 to 6 weeks after completion of neoadjuvant CRT. However, the optimal timing of surgery is not clearly defined. Methods: A total of 129 consecutive patients with locally advanced esophageal cancer, treated between 1998 and 2007, were retrospectively analyzed using prospectively collected data. Patients were divided into 3 groups on the basis of timing to surgery: group 1, <= 30 days (n = 17); group 2, 31 to 60 days (n = 83); and group 3, 61 to 90 days (n = 29). Subsequently, only 2-numerically more consistent-groups were studied, using the median value of timing intervals as a cutoff level: group A, <= 46 days (n = 66); and group B, >46 days (n = 63). Results: Groups were comparable in terms of patient and tumor characteristics, type of neoadjuvant regimen, toxicity, postoperative morbidity and mortality rates, tumor downstaging, and pathologic complete responses. The overall 5-year actuarial survival rate was 0% in group 1, 43.1% in group 2, and 35.9% in group 3 (P = 0.13). After R0 resection (n = 106), the 5-year actuarial survival rate was 0%, 51%, and 47.3%, respectively (P = 0.18). Tumor recurrence after R0 resection seemed to be inversely related, even if not significantly (P = 0.17), to the time interval between chemoradiation and surgery: 50% in group 1, 40.6% in group 2, and 21.7% in group 3. When considering only 2 groups, the overall 5-year survival was 33.1% in group A and 42.7% in group B (P = 0.64); after R0 resection, the 5-year survival was 37.8% and 56.3%, respectively (P = 0.18). The rate of tumor recurrence was significantly lower in group B (25%) than in group A (48.3%) (P = 0.02). Conclusion: Delayed surgery after neoadjuvant chemoradiation does not compromise the outcomes of patients with locally advanced SCC of the esophagus. Delaying surgery up to 90 days offers relevant advantages in the clinical management of the patients, can reduce tumor recurrences, and may improve prognosis after complete R0 resection surgery.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Oncology

Oncological outcomes of squamous cell carcinoma of the cervical esophagus treated with definitive (chemo-)radiotherapy: a systematic review and meta-analysis

Armando De Virgilio, Andrea Costantino, Bianca Maria Festa, Giuseppe Mercante, Davide Franceschini, Ciro Franzese, Marta Scorsetti, Andrea Marrari, Raffaele Cavina, Salvatore Marano, Carlo Castoro, Giuseppe Spriano

Summary: Definitive chemoradiotherapy is a valuable first-line treatment for cervical esophageal squamous cell carcinoma (CESCC) with favorable oncological outcomes. Further research is needed to identify survival predictors for stage-based clinical guidelines.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2023)

Article Gastroenterology & Hepatology

Identifying a core symptom set triggering radiological and endoscopic investigations for suspected recurrent esophago-gastric cancer: a modified Delphi consensus process

Swathikan Chidambaram, Nikhil M. Patel, Viknesh Sounderajah, Rita Alfieri, Luigi Bonavina, Edward Cheong, Andy Cockbain, Xavier Benoit D'Journo, Lorenzo Ferri, Ewen A. Griffiths, Peter Grimminger, Caroline Gronnier, Christian Gutschow, Jakob Hedberg, Joonas H. Kauppila, Sjoerd Lagarde, Donald Low, Philippe Nafteux, Grard Nieuwenhuijzen, Magnus Nilsson, Riccardo Rosati, Wolfgang Schroeder, B. Mark Smithers, Mark I. van Berge Henegouwen, Richard van Hillegesberg, David Watson, Ravinder Vohra, Nick Maynard, Sheraz R. Markar

Summary: Currently, there is a lack of evidence-based guidelines for surveillance of recurrence after esophageal and gastric (OG) cancer surgical resection. This study used a modified Delphi consensus process to identify eight symptoms that should prompt further investigations for suspected recurrent malignancy.

DISEASES OF THE ESOPHAGUS (2023)

Article Oncology

Influence of postoperative complications following esophagectomy for cancer on quality of life: A European multicenter study

N. Schuring, E. Jezerskyte, M. I. van Berge Henegouwen, M. A. G. Sprangers, P. Lagergren, A. Johar, S. R. Markar, S. S. Gisbertz

Summary: This study aimed to investigate the relationship between postoperative complications and long-term health-related quality of life (HRQL) in patients who underwent esophagectomy for cancer. The study found that patients with complications reported more dyspnea compared to those without complications, but these differences were not clinically significant. The severity of complications also had an impact on the patients' mood. Overall, HRQL in esophageal cancer patients is more likely affected by the complexity of the surgical procedure itself.
Review Otorhinolaryngology

Oncological outcomes of cervical esophageal cancer treated primarily with surgery: a systematic review and meta-analysis

Armando De Virgilio, Andrea Costantino, Bianca Maria Festa, Giuseppe Mercante, Davide Franceschini, Ciro Franzese, Marta Scorsetti, Andrea Marrari, Raffaele Cavina, Salvatore Marano, Carlo Castoro, Giuseppe Spriano

Summary: The study aims to determine the oncological outcomes of surgery for cervical esophageal cancer. The results showed different survival rates between larynx preserving surgery and non-preserving surgery, and further research is needed to compare the effects of surgery and chemoradiotherapy.

EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY (2023)

Article Ophthalmology

Determinants of Long-Term Survival in Metastatic Choroidal and Ciliary Body Melanoma

Elina S. Rantala, Raffaele Parrozzani, Micaela M. Hernberg, Vanna Chiarion-Sileni, Tero T. Kivela, Edoardo Midena

Summary: The study aims to build and validate a prognostic model for predicting long-term overall survival in metastatic choroidal and ciliary body melanoma. The study analyzed the predictors of intermediate and long-term survival in a Finnish cohort, and validated the models using an Italian cohort. The results showed that alkaline phosphatase or lactate dehydrogenase >2 times the upper normal limit essentially precluded long-term survival, and the most robust predictor was distant metastasis-free interval >42 months.

AMERICAN JOURNAL OF OPHTHALMOLOGY (2023)

Article Oncology

Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial

Paolo A. A. Ascierto, Mario Mandala, Pier Francesso Ferrucci, Massimo Guidoboni, Piotr Rutkowski, Virginia Ferraresi, Ana Arance, Michele Guida, Evaristo Maiello, Helen Gogas, Erika Richtig, Maria Teresa Fierro, Celeste Lebbe, Hildur Helgadottir, Paola Queirolo, Francesco Spagnolo, Marco Tucci, Michele Del Vecchio, Maria Gonzales Cao, Alessandro Marco Minisini, Sabino De Placido, Miguel F. F. Sanmamed, Domenico Mallardo, Marcello Curvietto, Ignacio Melero, Giuseppe Palmieri, Antonio M. Grimaldi, Diana Giannarelli, Reinhard Dummer, Vanna Chiarion Sileni

Summary: This study is a randomized, three-arm, noncomparative phase II trial that aims to explore sequential immunotherapy and BRAF/MEK inhibition for patients with BRAFV600-mutant metastatic melanoma. The results show that sequential immunotherapy and targeted therapy provide clinically meaningful survival benefits for patients.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Oncology

Tumor immune microenvironment in therapy-naive esophageal adenocarcinoma could predict the nodal status

Andromachi Kotsafti, Matteo Fassan, Francesco Cavallin, Valentina Angerilli, Luca Saadeh, Matteo Cagol, Rita Alfieri, Pierluigi Pilati, Carlo Castoro, Ignazio Castagliuolo, Melania Scarpa, Marco Scarpa

Summary: This study found that immune marker expression, oncogene status, and intra- and peritumoral immune infiltrating cells are associated with lymph node metastasis in patients with esophageal adenocarcinoma. These results suggest that immune surveillance failure is the key driver of lymph node metastasis.

CANCER MEDICINE (2023)

Article Oncology

Antigen rapid diagnostic test monitoring for SARS-CoV-2 in asymptomatic and fully vaccinated cancer patients: Is it cost-effective?

Mario Caccese, Anna Maria Saieva, Valentina Guarneri, Sara Lonardi, Massimo Cacco, Vanna Chiarion Sileni, Michele Gottardi, Eleonora Mioranza, Francesca Bergamo, Antonella Brunello, Vittorina Zagonel, Patrizia Benini

Summary: Routine testing for SARS-CoV-2 in asymptomatic and fully vaccinated cancer patients during treatment did not appear to be cost-effective. Out of 2439 cancer patients screened, only 2.17% tested positive, and 92.5% had their cancer treatment discontinued as a precaution.

CANCER MEDICINE (2023)

Article Oncology

Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial

Paolo Antonio Ascierto, Evan J. Lipson, Reinhard Dummer, James Larkin, Georgina V. Long, Rachel E. Sanborn, Vanna Chiarion-Sileni, Brigitte Dreno, Stephane Dalle, Dirk Schadendorf, Margaret K. Callahan, Marta Nyakas, Victoria Atkinson, Carlos Alberto Gomez-Roca, Naoya Yamazaki, Hussein A. Tawbi, Naomey Sarkis, Deepti Warad, Sonia Dolfi, Priyam Mitra, Satyendra Suryawanshi, Jean-Jacques Grob

Summary: Preliminary research shows that nivolumab and relatlimab have better efficacy in treating advanced melanoma patients who have previously received anti-PD-(L)1 treatment. The RELATIVITY-047 trial demonstrated that nivolumab and relatlimab, compared to nivolumab alone, significantly improved progression-free survival in previously untreated advanced melanoma patients.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Oncology

Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study

Paolo. A. Ascierto, Eleonora Cioli, Vanna Chiarion-Sileni, Pietro Quaglino, Francesco Spagnolo, Massimo Guidoboni, Michele Del Vecchio, Ketty Peris, Paola Queirolo, Luisa Fioretto, Corrado Caraco, Miriam Paone, Antonio Sorrentino, Mariaelena Capone, Diana Giannarelli, Gerardo Ferrara, Daniela Massi, Claudia Trojaniello

Summary: This study aims to investigate the efficacy of neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma. The study is a phase II, open-label, non-comparative trial in patients with stage IIIB/C/D surgically resectable melanoma. It is expected that the combination of neoadjuvant and adjuvant treatment may reduce the incidence of relapse and improve survival.

FRONTIERS IN ONCOLOGY (2023)

Article Oncology

Italian nivolumab Expanded Access Programme in melanoma adjuvant setting: patient outcomes and safety profile

Paolo A. Ascierto, Anna M. Di Giacomo, Vanna Chiarion Sileni, Paola Queirolo, Francesco Spagnolo, Federica De Galitiis, Francesco Cognetti, Mario Mandala, Massimo Guidoboni, Gaetana Rinaldi, Roberta Depenni, Francesca Consoli, Teresa Troiani, Michele Guida, Riccardo Marconcini, Pier F. Ferrucci, Sabino Strippoli, Paolo Fava, Barbara Merelli, Ester Simeone, Lorenza Di Guardo, Diana Giannarelli, Massimo Maio, Pietro Quaglino, Michele Del Vecchio

Summary: The CheckMate 238 study demonstrated the benefits of nivolumab over ipilimumab for melanoma patients and showed a tolerable safety profile. The Italian Expanded Access Programme enrolled 611 patients with resected melanoma and showed similar clinical activity and safety of nivolumab in a real-life setting.

EUROPEAN JOURNAL OF CANCER (2023)

Article Biochemistry & Molecular Biology

Molecular Modeling Unveils the Effective Interaction of B-RAF Inhibitors with Rare B-RAF Insertion Variants

Maria Chiara Scaini, Luisa Piccin, Davide Bassani, Antonio Scapinello, Stefania Pellegrini, Cristina Poggiana, Cristina Catoni, Debora Tonello, Jacopo Pigozzo, Luigi Dall'Olmo, Antonio Rosato, Stefano Moro, Vanna Chiarion-Sileni, Chiara Menin

Summary: The FDA has approved MAPK inhibitors for treating melanoma patients with BRAF gene mutation in the V600 codon. However, rare BRAF mutations outside the V600 codon may also cause melanoma, and their response to BRAF inhibitor treatment is still not well understood. In this study, a patient with a rare p.T599dup B-RAF mutation was found to have a good response to Dabrafenib/Trametinib targeted therapy. In-silico modeling showed that Dabrafenib could effectively bind to this rare mutation, suggesting the possibility of broadening the spectrum of BRAF inhibitor-sensitive mutations beyond the V600 codon.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Oncology

Outcomes in patients with BRAFV600-mutated melanoma and brain metastases at baseline treated with dabrafenib plus trametinib

Massimo Aglietta, Vanna Chiarion-Sileni, Paolo Fava, Massimo Guidoboni, Roberta Depenni, Alessandro Minisini, Francesca Consoli, Paolo Antonio Ascierto, Gaetana Rinaldi, Maria Banzi, Riccardo Marconcini, Rossana Gueli, Virginia Ferraresi, Marco Tucci, Giuseppe Tonini, Giovanni Lo Re, Michele Guida, Michele Del Vecchio, Ilaria Gioia Marcon, Paola Queirolo

Summary: Brain metastases and high LDH levels are associated with poor prognosis in melanoma patients. The effectiveness of dabrafenib plus trametinib in patients with brain metastases is limited.

TUMORI JOURNAL (2023)

Meeting Abstract Oncology

Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study

Jason J. Luke, Paolo Antonio Ascierto, Muhammad Adnan Khattak, Luis de la Cruz Merino, Michele Del Vecchio, Piotr Rutkowski, Francesco Spagnolo, Jacek Mackiewicz, Vanna Chiarion-Sileni, John M. M. Kirkwood, Caroline Robert, Jean-Jacques Grob, Federica de Galitiis, Dirk Schadendorf, Matteo S. Carlino, Larry Wu, Mizuho Fukunaga-Kalabis, Clemens Krepler, Alexander M. Eggermont, Georgina V. Long

JOURNAL OF CLINICAL ONCOLOGY (2023)

Meeting Abstract Gastroenterology & Hepatology

Colitis due to immunotherapy with anti-PD-1: a case series

M. De Ruvo, B. Barberio, F. Zingone, L. Bonanno, A. Dal Maso, F. Stefano, V. Chiarion Sileni, E. V. Savarino

JOURNAL OF CROHNS & COLITIS (2023)

No Data Available